MAZE · Company research
Maze Therapeutics, Inc. (MAZE): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
21records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| What Makes Maze Therapeutics, Inc. (MAZE) a New Buy Stock | Maze Therapeutics, Inc. (MAZE) has been upgraded to a Zacks Rank #2 (Buy) rating, primarily driven by upward trends in earnings estimates. The company's Zacks Consensus Estimate has increased 1.2% over the past three months. The upgrade positions MAZE in the top 20% of Zacks-covered stocks, suggesting potential for near-term stock price appreciation based on improving earnings outlook. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bullish | 1 | 1 |
| How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39% | Maze Therapeutics (MAZE) stock has gained 22.3% over the past four weeks and closed at $27.53. Wall Street analysts project a mean price target of $61.50, indicating potential upside of 123.4%. The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions, though the article cautions that price targets alone should not be the sole basis for investment decisions. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bullish | 1 | 1 |
| Maze Therapeutics CEO Jason Coloma sells $932,259 in Maze shares - Investing.com | Maze Therapeutics CEO Jason Coloma sells $932,259 in Maze shares Investing.com | View source ↗ | Investing.com | Oct 18, 2026 | neutral | 0 | 0.6 |
| MAZE Nov 2026 12.500 put (MAZE261120P00012500) Interactive Stock Chart - Yahoo! Finance Canada | MAZE Nov 2026 12.500 put (MAZE261120P00012500) Interactive Stock Chart Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 16, 2026 | neutral | 0 | 0.6 |
| MAZE Nov 2026 22.500 call (MAZE261120C00022500) Stock Price, News, Quote & History - Yahoo! Finance Canada | MAZE Nov 2026 22.500 call (MAZE261120C00022500) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 16, 2026 | neutral | 0 | 0.6 |
| Maze Therapeutics, Inc. (MAZE) stock price, news, quote and history - Yahoo Finance UK | Maze Therapeutics, Inc. (MAZE) stock price, news, quote and history Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 14, 2026 | neutral | 0 | 0.6 |
| MAZE Oct 2026 25.000 call (MAZE261016C00025000) Interactive Stock Chart - Yahoo! Finance Canada | MAZE Oct 2026 25.000 call (MAZE261016C00025000) Interactive Stock Chart Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 10, 2026 | neutral | 0 | 0.6 |
| Maze Therapeutics (NasdaqGM:MAZE) Stock Forecast & Analyst Predictions - Simply Wall Street | Maze Therapeutics (NasdaqGM:MAZE) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 9, 2026 | neutral | 0 | 0.6 |
| How MAZE Group (MAZE) Affects Rotational Strategy Timing - Stock Traders Daily | How MAZE Group (MAZE) Affects Rotational Strategy Timing Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 8, 2026 | neutral | 0 | 0.6 |
| Maze Therapeutics, Inc. (MAZE) Stock Price, News, Quote & History - Yahoo! Finance Canada | Maze Therapeutics, Inc. (MAZE) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 7, 2026 | neutral | 0 | 0.6 |
| Maze Therapeutics (NasdaqGM:MAZE) Stock Price - Simply Wall Street | Maze Therapeutics (NasdaqGM:MAZE) Stock Price Simply Wall Street | View source ↗ | Simply Wall Street | Oct 6, 2026 | neutral | 0 | 0.6 |
| A kidney poster will share early research on reducing toxin uptake to limit injury - Stock Titan | A kidney poster will share early research on reducing toxin uptake to limit injury Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| 3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight - MarketBeat | 3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight MarketBeat | View source ↗ | MarketBeat | Oct 6, 2026 | neutral | 0 | 0.6 |
| After exercising options, Harold Bernstein sold 16,141 Maze Therapeutics (MAZE) shares. - Stock Titan | After exercising options, Harold Bernstein sold 16,141 Maze Therapeutics (MAZE) shares. Stock Titan | View source ↗ | Stock Titan | Oct 2, 2026 | neutral | 0 | 0.6 |
| An officer plans to sell 16,141 Maze Therapeutics (MAZE) shares on October 1, 2026. - Stock Titan | An officer plans to sell 16,141 Maze Therapeutics (MAZE) shares on October 1, 2026. Stock Titan | View source ↗ | Stock Titan | Oct 1, 2026 | neutral | 0 | 0.6 |
| Why is Maze Therapeutics stock climbing today? - Investing.com | Why is Maze Therapeutics stock climbing today? Investing.com | View source ↗ | Investing.com | Sep 23, 2026 | neutral | 0 | 0.6 |
| Maze Therapeutics Shares Rise 2.9% After CIBC Initiates Coverage - Yahoo Finance | Maze Therapeutics Shares Rise 2.9% After CIBC Initiates Coverage Yahoo Finance | View source ↗ | Yahoo Finance | Sep 23, 2026 | neutral | 0 | 0.6 |
| The Surprise That Sent Vertex — And Its Chief Rival — Soaring - Investor's Business Daily | The Surprise That Sent Vertex — And Its Chief Rival — Soaring Investor's Business Daily | View source ↗ | Investor's Business Daily | Sep 22, 2026 | neutral | 0 | 0.6 |
| $MAZE stock is down 10% today. Here's what we see in our data. | MAZE Stock News - Quiver Quantitative | $MAZE stock is down 10% today. Here's what we see in our data. | MAZE Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 10, 2026 | neutral | 0 | 0.6 |
| MAZE Forecast — Price Target — Prediction for 2027 - TradingView | MAZE Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 26, 2026 | neutral | 0 | 0.6 |
| After ph. 2 readout, analysts herald 'best-in-class potential' for Maze kidney candidate as stock plummets - Fierce Biotech | After ph. 2 readout, analysts herald 'best-in-class potential' for Maze kidney candidate as stock plummets Fierce Biotech | View source ↗ | Fierce Biotech | Mar 25, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.